266. Familial mediterranean fever Clinical trials / Disease details
Clinical trials : 28 / Drugs : 22 - (DrugBank : 5) / Drug target genes : 14 - Drug target pathways : 59
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03446209 (ClinicalTrials.gov) | April 23, 2018 | 11/12/2017 | Tocilizumab for the Treatment of Familial Mediterranean Fever | Tocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept Study | Familial Mediterranean Fever | Drug: Tocilizumab Infusion RoAcemtra (EU);Drug: 0.9% physiological saline | University Hospital Tuebingen | NULL | Completed | 18 Years | 64 Years | All | 30 | Phase 2 | Germany |